Journal of Medicinal Chemistry · 2005 · 94 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyBioavailabilityBone MetabolismDrug DesignBone Metabolism PharmacotherapyEnzyme InhibitionLead Compound DesignNatural Product-based Drug DesignOsteoporosis PharmacotherapyAmino Acid-based InhibitorsAnti-resorptive TherapyBone Resorption InhibitionCathepsin ActivityDrug Distribution To BoneOsteoclast-mediated Bone DestructionOsteoclast-mediated Bone LossOsteoclast-mediated Bone Remodeling
We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.
16
Proteolytic Activity of Human Osteoclast Cathepsin K
Mary J. Bossard, Thaddeus A. Tomaszek, Scott K. Thompson et al. · Journal of Biological Chemistry · 1996 · 491 citations · Full text